SK bioscience Receives Emergency Use Listing for SKYCovione
Wednesday, June 21, 2023
SK Bioscience has announced that its COVID-19 vaccine, SKYCovione, has been granted Emergency Use Listing by the World Health Organisation.
SKYCovione is a self-assembled nanoparticle vaccine that specifically targets the receptor binding domain of the SARS-CoV-2 Spike protein, which is responsible for the virus's entry into human cells. Based on the immunogenicity and safety profile, SKYCovione becomes the 12th COVID-19 vaccine to be granted Emergency Use Listing.
SKYCovione is the world’s first medicine developed using computational protein design, an approach that uses Rosetta software to engineer protein structures with enough precision to place individual atoms exactly where desired.
In Phase III clinical trials, SKYCovione demonstrated the ability to induce neutralising antibody responses against the parent strain of SARS-CoV-2.
